Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

189.60 +1.80 (+0.96%)
Streaming Delayed Price Updated: 3:58 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
59 60 Next >
News headline image
Comparative Study: Biogen And Industry Competitors In Biotechnology Industry ↗
 
Via Benzinga
News headline image
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others ↗
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this  
Via Benzinga
News headline image
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning ↗
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
News headline image
Here's How Much $1000 Invested In Biogen 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry ↗
 
Via Benzinga
News headline image
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review ↗
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
News headline image
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks? ↗
The real competitive battle is about to begin, and it will last a long time. 
Via The Motley Fool
News headline image
These Analysts Revise Their Forecasts On Biogen After Q3 Results ↗
Biogen Inc (NASDAQ: BIIB) reported better-than-expected third-quarter earnings. 
Via Benzinga
News headline image
Expert Ratings for Biogen ↗
 
Via Benzinga
News headline image
Thoughts For Thursday: Staying On Top - Barely ↗
The stock market continues to be full of worry, but is managing to stay on top this week, so far. It is worth noting that yesterday's close brought levels back to those of a month ago. 
Via Talk Markets
News headline image
Biogen (BIIB) Q3 2023 Earnings Call Transcript ↗
BIIB earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides ↗
Biogen Inc (NASDAQ: BIIB) posted Q3 FY23 sales of $2.53 billion, beating the con 
Via Benzinga
News headline image
Looking Into Biogen's Recent Short Interest ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
Assessing Biogen's Performance Against Competitors In Biotechnology Industry ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Compared To Estimates, Biogen Inc. Q3 Earnings: A Look At Key Metrics ↗
Biogen Inc. reported $2.53 billion in revenue for the quarter ended September 2023. 
Via Talk Markets
News headline image
US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings ↗
Stock futures indicate a subdued opening on Wednesday after several consecutive gains in major averages. Traders are eagerly awaiting Federal Reserve Chair Jerome Powell’s speech for insights into... 
Via Benzinga
Topics Economy
News headline image
$1000 Invested In Biogen 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount ↗
The company shares in the profits and sales related to Alzheimer's treatment, Leqembi. 
Via Investor's Business Daily
News headline image
3 Biotech Moonshots to Bet on the Future of Health ↗
Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk. 
Via InvestorPlace
Topics Intellectual Property
News headline image
Biogen Appoints Monish Patolawala to its Board of Directors
Accomplished executive brings deep expertise leading global financial organizations and overseeing successful business transformation 
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment ↗
Both companies are working on under-the-skin injections for Alzheimer's treatment. 
Via Investor's Business Daily
News headline image
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease ↗
Biogen Inc. (NASDAQ: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, 
Via Benzinga
News headline image
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
News headline image
An Oversold Small Cap Industrial That Insiders Are Buying Ahead Of Earnings This Week ↗
Another RSI Buy In a post last month, we wrote about the power of RSI (Relative Strength Index) as a technical indicator (Relative Strength Index) in relation to Stitch Fix, Inc. (NASDAQ: SFIX)  
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Struggling Stocks Investors Shouldn't Buy on the Dip ↗
These stocks have been brutal investments to own in recent years -- and investors shouldn't expect things to get better. 
Via The Motley Fool
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.